GET DAILY SIGNALSNeurAxis (NRXS) Reports +80% Revenue Growth as Reimbursement Expands
Key Takeaways
- NeurAxis (NRXS) is a medical technology company focused on neuromodulation therapies for gut-brain interaction disorders, led by its IB-Stim PENFS device.
- The stock has traded in a broad range in recent months, with notable spikes in trading volume in mid-September and mid-October.
- Q1 2026 results showed an 80% year-over-year revenue increase to $1.6 million, reflecting early commercial traction.
- The company secured a Category 1 CPT code and expanded its covered-lives base past 100 million, a key driver of reimbursement growth.
- NeurAxis remains unprofitable, with a net loss of $1.8 million in Q1 2026, though the loss narrowed 23% from the prior year.
- A federal supply schedule contract opens access to the U.S. Department of Veterans Affairs and its patient network.
Current Market Snapshot
NeurAxis shares have shown notable volatility over recent months, trading within a range that has seen the stock climb from roughly the mid-$5 level to above $8 intraday before consolidating. Trading activity has been punctuated by elevated volume sessions, suggesting periodic shifts in investor interest in the small-cap medical technology name. As a growth-stage company with a modest market capitalization, NRXS can experience outsized price swings relative to broader healthcare benchmarks, reflecting both its commercialization progress and the inherent risks of an early-stage commercial rollout. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
NeurAxis (NRXS) Business Overview and Competitive Position
NeurAxis, Inc. is a medical technology company headquartered in Carmel, Indiana, that develops neuromodulation therapies for chronic and debilitating conditions affecting the gastrointestinal system, specifically disorders of gut-brain interaction in pediatric and adult patients. Its flagship product, IB-Stim, uses Percutaneous Electrical Nerve Field Stimulation (PENFS) technology and is indicated for patients eight years and older with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia, and related nausea. The company also markets the RED (Rectal Expulsion Device), a screening tool used to evaluate neuromuscular evacuation function and detect rectal hypersensitivity.
The company competes in a specialized segment of neuromodulation where reimbursement adoption and clinical workflow integration are decisive factors. Its competitive strengths include a differentiated, non-surgical device platform, an expanding base of payer coverage, and a targeted focus on pediatric and adolescent gastrointestinal disorders where treatment options have historically been limited. Investors follow NRXS closely because its growth hinges on payer coverage expansion and hospital adoption rather than on a single product launch.
Recent Developments Driving NRXS
NeurAxis reported 80% year-over-year revenue growth in the first quarter of 2026, reaching $1.6 million compared with $896,000 in the prior-year period. Management attributed part of the improvement to a 33% increase in the average selling price of its IB-Stim device, reflecting a favorable shift in the reimbursement mix. The company also reported a net loss of $1.8 million, a 23% improvement from the prior year, while its cash burn rate stood at $1.2 million for the quarter.
A central catalyst has been the introduction of a Category 1 CPT code for the company's therapy, which has helped drive a gradual expansion in payer coverage. NeurAxis reported more than 100 million covered lives, including a major national health insurer policy covering approximately 45 million members. The company was also awarded a federal supply schedule contract providing access to the U.S. Department of Veterans Affairs. At the same time, management noted that coverage adoption remains gradual, with delays in some state Medicaid programs loading the new CPT code affecting hospital activation. The company has continued to expand its commercial, sales, and payer-access teams to support growth, and it anticipated a one-time, non-recurring stock compensation charge in the second quarter of 2026.
2026 Outlook and What Investors Should Watch
Looking ahead, the primary factors shaping NeurAxis's trajectory in 2026 center on commercial execution and reimbursement expansion. Investors are likely to monitor the pace of revenue growth relative to management's stated path toward cash flow breakeven, which the company has indicated requires roughly $15 million in annual revenue. The continued rollout of the Category 1 CPT code across commercial and state Medicaid payers will be critical, as broader coverage directly supports higher utilization and reduces the need for patient financial assistance.
Additional items to watch include the company's progress with the Department of Veterans Affairs channel, changes in the average selling price, quarterly cash burn, and the impact of the expanded sales organization on account activation. As a small-cap, growth-stage medical device company, NeurAxis also remains sensitive to broader market conditions, healthcare reimbursement policy, and investor sentiment toward pre-profitability healthcare names. These factors, rather than any single event, are likely to determine the stock's direction over the remainder of 2026. From what I see, I’m watching the reimbursement momentum closely here.
Exploring AI Tools for Market Analysis
In my own work, I often review Tickeron’s Trending AI Robots page to see how automated strategies are positioned across various tickers. It offers a curated look at top-performing bots with different approaches, which can provide additional context when evaluating names like NRXS alongside traditional analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for NRXS turns positive, indicating new upward trend
NRXS saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 67 similar instances where the indicator turned positive. In 62 of the 67 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
NRXS moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for NRXS crossed bullishly above the 50-day moving average on September 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +19.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where NRXS advanced for three days, in 122 of 146 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
NRXS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day RSI Indicator for NRXS moved out of overbought territory on September 25, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In 14 of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 30 of 32 cases where NRXS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for NRXS turned negative on October 27, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 30 similar instances when the indicator turned negative. In 29 of the 30 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRXS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. NRXS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 48 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.526) is normal, around the industry mean (2.974). P/E Ratio (-9.539) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (14.225) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement